Form 4: ONCY Director Wayne Pisano Increases Stake

ONCOLYTICS BIOTECH Director Wayne Pisano acquired 30,000 common shares at a weighted average price of $0.8446.

Summary

• Wayne Pisano, a Director of ONCOLYTICS BIOTECH INC (ONCY), purchased 30,000 common shares.
• The transaction occurred on February 12, 2026.
• The shares were acquired at a weighted average price of $0.8446 per share, with prices ranging from $0.83 to $0.85.
• Following this transaction, Mr. Pisano beneficially owns 492,414 common shares directly.
• The transaction was made pursuant to a Rule 10b5-1(c) plan.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a strong positive signal, as a director's decision to increase their personal stake often reflects deep conviction in the company's future prospects and current valuation.

Positives

• A company director, Wayne Pisano, increased his direct ownership in ONCOLYTICS BIOTECH INC by purchasing 30,000 common shares.
• The purchase price of $0.8446 per share indicates management's confidence in the company's current valuation and future prospects.
• The transaction was made pursuant to a Rule 10b5-1 plan, suggesting a pre-planned investment strategy and reducing concerns about opportunistic timing.

Future Outlook

This Form 4 filing does not contain forward-looking statements or guidance regarding the company's future performance or strategic direction.

Industry Context

StockSavvy.ai notes that insider purchases, especially by a director, are often interpreted by the market as a positive signal, indicating that those closest to the company believe its shares are undervalued or expect positive developments. This can sometimes precede periods of outperformance relative to broader industry trends, as it suggests confidence in the company's strategic direction and operational execution.

Comparison to Industry Standards

• Insider buying activity is generally viewed positively across all industries. While specific comparable companies or projects are not detailed in this filing, a director increasing their stake is a strong indicator of internal confidence, often more impactful than general market sentiment or analyst ratings.
• For example, similar insider purchases in the biotech sector, such as those seen in early-stage pharmaceutical companies, often precede significant clinical trial milestones or regulatory approvals, signaling management's belief in upcoming catalysts.

Related Party Transactions

• Director Wayne Pisano, a related party, acquired 30,000 common shares of ONCOLYTICS BIOTECH INC.

Stakeholder Impact

• Shareholders may view this insider purchase as a positive indicator of management's confidence in the company's value and future performance, potentially boosting investor sentiment.
• Employees might interpret the director's increased stake as a sign of stability and belief in the company's long-term vision.

Key Dates

Recommendation

A director's decision to significantly increase their personal stake in the company, especially through open market purchases, is a strong vote of confidence. This insider buying suggests that Wayne Pisano, with his intimate knowledge of ONCOLYTICS BIOTECH, believes the shares are currently undervalued and expects positive developments. This often signals potential upside for the stock, making it an attractive 'buy' for seasoned investors looking for conviction from within the company.

Keywords

ONCOLYTICS BIOTECH, ONCY, insider buying, director purchase, common shares, Form 4, Wayne Pisano, equity acquisition, Rule 10b5-1